cefapirin
Trade name: Cefadyl
Approved
Jun 1, 1973
Cephapirin is a first-generation cephalosporin. Cephapirin has been indicated for the treatment of infections when caused by susceptible strains in respiratory, genitourinary, gastrointestinal, skin and soft tissue, bone and joint infections, septicemia; treatment of susceptible gram-positive bacilli and cocci (never enterococcus); some gram-negative bacilli including E. coli, Proteus, and Klebsiella may be susceptible. Cephapirin is used in veterinary as an intra-uterine antibiotic infusion for the treatment of subacute and chronic endometritis in cows and repeat breeders. — NCATS
Clinical trial activity
1 trials · 1 clinical orgs · 5 marketing orgs
Earliest trial started Oct 31, 2008 (NCT03877289)
Timeline
1970s
- Jun 1, 1973
Earliest FDA Approval
- Mar 12, 1974
Apothecon — Marketing Organization
1980s
- Jul 2, 1987
West-Ward Pharmaceutical — Marketing Organization
- Jul 2, 1987
Hikma — Marketing Organization
Indications
Approved for
Studied for
Mechanism of action
- Bacterial penicillin-binding proteinINHIBITOR
Bacterial penicillin-binding protein inhibitor
- D-alanyl-D-alanine carboxypeptidase DacB (dacB) ↗
- Peptidoglycan D,D-transpeptidase FtsI (ftsI) ↗
- Penicillin-binding protein 1A (mrcA) ↗
- Penicillin-binding protein 1B (mrcB) ↗
- D-alanyl-D-alanine carboxypeptidase DacA (dacA) ↗
- Peptidoglycan D,D-transpeptidase MrdA (mrdA) ↗
- D-alanyl-D-alanine carboxypeptidase DacC (dacC) ↗
Approval history
- approvedJun 1, 1973
Chemistry & pharmacology
SMILES
CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)CSc3ccncc3)[C@H]2SC1- Mol. weight
- 423.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1599 ↗
- WikipediaCefapirin ↗
- NCATS89B59H32VN ↗
- ChEMBLCHEMBL1201043 ↗
Also known as
- (6r,7r)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- (6r,7r)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- bl-p-1322
- bl-p-1322
- cefadyl
- cefadyl
- cefadyl
- cefapirin
- cefapirin
- cefapirin
- cefapirin
- cefapirin
- cefapirin
- cefapirina
- cefapirina
- cefapirine
- cefapirine
- cefapirin sodium
- cefapirin sodium
- cefapirin sodium
- cefapirin sodium
- cefapirin sodium
- cefapirin sodium
- cefapirinum
- cefapirinum
- cefaprin
- cefaprin
- cefaprin
- cephapirin
- cephapirin
- cephapirin
- cephapirin
- cephapirin
- cephapirin
- cephapirine
- cephapirine
- cephapirine
- cephapirin sodium
- cephapirin sodium
- cephapirin sodium
- cephapirin sodium
- cephaprin
- cepr
- cepr
- sodium cefapirin
- sodium cefapirin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03877289 | Phase 4 | Oct 31, 2008 | University of Calgary |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Calgary | Academic/Hospital | 1 | 1 | 1 | 2008 |